The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II open-label study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune-checkpoint inhibitor: The BREAKPOINT trial.
 
Elena Verzoni
Consulting or Advisory Role - Ipsen; Janssen; Novartis; Pfizer
 
Alessandra Bearz
No Relationships to Disclose
 
Ugo De Giorgi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Pfizer; Sanofi
 
Franco Nole
No Relationships to Disclose
 
Camillo Porta
No Relationships to Disclose
 
Raffaele Ratta
No Relationships to Disclose
 
Melanie Claps
No Relationships to Disclose
 
Filippo Pagani
No Relationships to Disclose
 
Antonia Martinetti
No Relationships to Disclose
 
Agata Cova
No Relationships to Disclose
 
Licia Rivoltini
No Relationships to Disclose
 
Filippo G. De Braud
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Dompè; Ignyta; Novartis; Pfizer; SERVIER; Tiziana Life Sciences
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; SERVIER
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Ignyta (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Nektar; Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Giuseppe Procopio
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer